Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05806580 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: May 1, 2022 to May 1, 2023 Interventions: Relmacabtagene Autoleucel Injection (Drug) to Relma-cel (Drug) · Eligibility criteria shortened, about 61 words · Study description shortened, about 135 wordsv4 Show 3 more changesShow less
    • Interventions: Relmacabtagene Autoleucel Injection (Drug) to Relma-cel (Drug)
    • Eligibility criteria shortened, about 61 words
    • Study description shortened, about 135 words

    See this version in full on ClinicalTrials.gov ↗

  2. Eligibility criteria shortened, about 1 wordv3 See this version in full on ClinicalTrials.gov ↗
  3. Site contact updated Study title shortened, about 6 words · Eligibility criteria shortened, about 1 wordv2 Show 2 more changesShow less
    • Study title shortened, about 6 words
    • Eligibility criteria shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To observe the efficacy and safety of a second infusion of relma-cel injection in patients with relapsed or refractory B-cell lymphoma.
Trial Details
NCT Number NCT05806580
Lead Sponsor Ruijin Hospital
Conditions Relapsed or Refractory B-cell Lymphoma
Enrollment 8 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov